Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 155 entries
Sorted by: Best Match Show Resources per page
Salivary biomarkers in psychobiological medicine.

Bioinformation

Chiappelli F, Iribarren FJ, Prolo P.
PMID: 17597915
Bioinformation. 2006 Dec 29;1(8):331-4. doi: 10.6026/97320630001331.

The value of salivary biomarkers for diagnostic and prognostic assessments has become increasingly well established in medicine, pharmacology, and dentistry. Certain salivary components mirror the neuro-endocrine status of the organism. Other saliva products are protein in nature, and can...

Cite
Chiappelli F, Iribarren FJ, Prolo P. Salivary biomarkers in psychobiological medicine. Bioinformation. 2006;1(8):331-4doi: 10.6026/97320630001331.
Chiappelli, F., Iribarren, F. J., & Prolo, P. (2006). Salivary biomarkers in psychobiological medicine. Bioinformation, 1(8), 331-4. https://doi.org/10.6026/97320630001331
Chiappelli, Francesco, et al. "Salivary biomarkers in psychobiological medicine." Bioinformation vol. 1,8 (2006): 331-4. doi: https://doi.org/10.6026/97320630001331
Chiappelli F, Iribarren FJ, Prolo P. Salivary biomarkers in psychobiological medicine. Bioinformation. 2006 Dec 29;1(8):331-4. doi: 10.6026/97320630001331. PMID: 17597915; PMCID: PMC1891707.
Copy Download .nbib Format: NLM
Comments on: A review on empirical likelihood methods for regression.

Test (Madrid, Spain)

Li G, Lu X.
PMID: 21152356
Test (Madr). 2009 Nov 01;18(3):463-467. doi: 10.1007/s11749-009-0165-7.

No abstract available.

Cite
Li G, Lu X. Comments on: A review on empirical likelihood methods for regression. Test (Madr). 2009;18(3):463-467doi: 10.1007/s11749-009-0165-7.
Li, G., & Lu, X. (2009). Comments on: A review on empirical likelihood methods for regression. Test (Madrid, Spain), 18(3), 463-467. https://doi.org/10.1007/s11749-009-0165-7
Li, Gang, and Lu, Xuyang. "Comments on: A review on empirical likelihood methods for regression." Test (Madrid, Spain) vol. 18,3 (2009): 463-467. doi: https://doi.org/10.1007/s11749-009-0165-7
Li G, Lu X. Comments on: A review on empirical likelihood methods for regression. Test (Madr). 2009 Nov 01;18(3):463-467. doi: 10.1007/s11749-009-0165-7. PMID: 21152356; PMCID: PMC2996722.
Copy Download .nbib Format: NLM
Molecular epigenetics, chromatin, and NeuroAIDS/HIV: immunopathological implications.

Bioinformation

Chiappelli F, Shapshak P, Commins D, Singer E, Minagar A, Oluwadara O, Prolo P, Pellionisz AJ.
PMID: 19052666
Bioinformation. 2008;3(1):47-52. doi: 10.6026/97320630003047. Epub 2008 Oct 07.

Epigenetics studies factors related to the organism and environment that modulate inheritance from generation to generation. Molecular epigenetics examines non-coding DNA (ncdDNA) vs. coding DNA (cdDNA), and pertains to every domain of physiology, including immune and brain function. Molecular...

Cite
Chiappelli F, Shapshak P, Commins D, et al. Molecular epigenetics, chromatin, and NeuroAIDS/HIV: immunopathological implications. Bioinformation. 2008;3(1):47-52doi: 10.6026/97320630003047.
Chiappelli, F., Shapshak, P., Commins, D., Singer, E., Minagar, A., Oluwadara, O., Prolo, P., & Pellionisz, A. J. (2008). Molecular epigenetics, chromatin, and NeuroAIDS/HIV: immunopathological implications. Bioinformation, 3(1), 47-52. https://doi.org/10.6026/97320630003047
Chiappelli, Francesco, et al. "Molecular epigenetics, chromatin, and NeuroAIDS/HIV: immunopathological implications." Bioinformation vol. 3,1 (2008): 47-52. doi: https://doi.org/10.6026/97320630003047
Chiappelli F, Shapshak P, Commins D, Singer E, Minagar A, Oluwadara O, Prolo P, Pellionisz AJ. Molecular epigenetics, chromatin, and NeuroAIDS/HIV: immunopathological implications. Bioinformation. 2008;3(1):47-52. doi: 10.6026/97320630003047. Epub 2008 Oct 07. PMID: 19052666; PMCID: PMC2586137.
Copy Download .nbib Format: NLM
Empirical likelihood analysis of the Buckley-James estimator.

Journal of multivariate analysis

Zhou M, Li G.
PMID: 19018294
J Multivar Anal. 2008 Apr;99(4):649-664. doi: 10.1016/j.jmva.2007.02.007.

The censored linear regression model, also referred to as the accelerated failure time (AFT) model when the logarithm of the survival time is used as the response variable, is widely seen as an alternative to the popular Cox model...

Cite
Zhou M, Li G. Empirical likelihood analysis of the Buckley-James estimator. J Multivar Anal. 2008;99(4):649-664doi: 10.1016/j.jmva.2007.02.007.
Zhou, M., & Li, G. (2008). Empirical likelihood analysis of the Buckley-James estimator. Journal of multivariate analysis, 99(4), 649-664. https://doi.org/10.1016/j.jmva.2007.02.007
Zhou, Mai, and Li, Gang. "Empirical likelihood analysis of the Buckley-James estimator." Journal of multivariate analysis vol. 99,4 (2008): 649-664. doi: https://doi.org/10.1016/j.jmva.2007.02.007
Zhou M, Li G. Empirical likelihood analysis of the Buckley-James estimator. J Multivar Anal. 2008 Apr;99(4):649-664. doi: 10.1016/j.jmva.2007.02.007. PMID: 19018294; PMCID: PMC2583435.
Copy Download .nbib Format: NLM
Analysis of Two-sample Censored Data Using a Semiparametric Mixture Model.

Acta mathematica Sinica, English series

Li G, Lin CT.
PMID: 20622987
Acta Math Sin Engl Ser. 2009 Jul;25(3):389-398. doi: 10.1007/s10255-008-8804-4.

In this article we study a semiparametric mixture model for the two-sample problem with right censored data. The model implies that the densities for the continuous outcomes are related by a parametric tilt but otherwise unspecified. It provides a...

Cite
Li G, Lin CT. Analysis of Two-sample Censored Data Using a Semiparametric Mixture Model. Acta Math Sin Engl Ser. 2009;25(3):389-398doi: 10.1007/s10255-008-8804-4.
Li, G., & Lin, C. T. (2009). Analysis of Two-sample Censored Data Using a Semiparametric Mixture Model. Acta mathematica Sinica, English series, 25(3), 389-398. https://doi.org/10.1007/s10255-008-8804-4
Li, Gang, and Lin, Chien-Tai. "Analysis of Two-sample Censored Data Using a Semiparametric Mixture Model." Acta mathematica Sinica, English series vol. 25,3 (2009): 389-398. doi: https://doi.org/10.1007/s10255-008-8804-4
Li G, Lin CT. Analysis of Two-sample Censored Data Using a Semiparametric Mixture Model. Acta Math Sin Engl Ser. 2009 Jul;25(3):389-398. doi: 10.1007/s10255-008-8804-4. PMID: 20622987; PMCID: PMC2901133.
Copy Download .nbib Format: NLM
Serum Fatty acids and risk of cutaneous melanoma: a population-based case-control study.

Dermatology research and practice

Vinceti M, Malagoli C, Iacuzio L, Crespi CM, Sieri S, Krogh V, Marmiroli S, Pellacani G, Venturelli E.
PMID: 23431289
Dermatol Res Pract. 2013;2013:659394. doi: 10.1155/2013/659394. Epub 2013 Jan 28.

Background. Some observational studies have suggested that excess dietary intake of polyunsaturated fatty acids such as linoleic acid increases cutaneous melanoma risk. We aimed at examining the association between serum fatty acids and melanoma risk by conducting a population-based...

Cite
Vinceti M, Malagoli C, Iacuzio L, et al. Serum Fatty acids and risk of cutaneous melanoma: a population-based case-control study. Dermatol Res Pract. 2013;2013:659394doi: 10.1155/2013/659394.
Vinceti, M., Malagoli, C., Iacuzio, L., Crespi, C. M., Sieri, S., Krogh, V., Marmiroli, S., Pellacani, G., & Venturelli, E. (2013). Serum Fatty acids and risk of cutaneous melanoma: a population-based case-control study. Dermatology research and practice, 2013659394. https://doi.org/10.1155/2013/659394
Vinceti, Marco, et al. "Serum Fatty acids and risk of cutaneous melanoma: a population-based case-control study." Dermatology research and practice vol. 2013 (2013): 659394. doi: https://doi.org/10.1155/2013/659394
Vinceti M, Malagoli C, Iacuzio L, Crespi CM, Sieri S, Krogh V, Marmiroli S, Pellacani G, Venturelli E. Serum Fatty acids and risk of cutaneous melanoma: a population-based case-control study. Dermatol Res Pract. 2013;2013:659394. doi: 10.1155/2013/659394. Epub 2013 Jan 28. PMID: 23431289; PMCID: PMC3569884.
Copy Download .nbib Format: NLM
Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters.

World journal of radiology

Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K.
PMID: 25071888
World J Radiol. 2014 Jul 28;6(7):480-5. doi: 10.4329/wjr.v6.i7.480.

Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer. Different radionuclides that emit β-rays such as (153)Samarium and (89)Strontium and achieve palliation are commercially available. In contrast to β-emitters,...

Cite
Wieder HA, Lassmann M, Allen-Auerbach MS, et al. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol. 2014;6(7):480-5doi: 10.4329/wjr.v6.i7.480.
Wieder, H. A., Lassmann, M., Allen-Auerbach, M. S., Czernin, J., & Herrmann, K. (2014). Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World journal of radiology, 6(7), 480-5. https://doi.org/10.4329/wjr.v6.i7.480
Wieder, Hinrich A, et al. "Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters." World journal of radiology vol. 6,7 (2014): 480-5. doi: https://doi.org/10.4329/wjr.v6.i7.480
Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol. 2014 Jul 28;6(7):480-5. doi: 10.4329/wjr.v6.i7.480. PMID: 25071888; PMCID: PMC4109099.
Copy Download .nbib Format: NLM
Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity.

BioProcess international

Gagnon P, Cheung CW, Lepin EJ, Wu AM, Sherman MA, Raubitschek AA, Yazaki PJ.
PMID: 21984873
Bioprocess Int. 2010 Feb;8(2):26-35.

This case study describes early phase purification process development for a recombinant anticancer minibody produced in mammalian cell culture. The minibody did not bind to protein A. Cation-exchange, anion-exchange, hydrophobic-interaction, and hydroxyapatite (eluted by phosphate gradient) chromatographic methods were...

Cite
Gagnon P, Cheung CW, Lepin EJ, et al. Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity. Bioprocess Int. 2010;8(2):26-35
Gagnon, P., Cheung, C. W., Lepin, E. J., Wu, A. M., Sherman, M. A., Raubitschek, A. A., & Yazaki, P. J. (2010). Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity. BioProcess international, 8(2), 26-35.
Gagnon, Pete, et al. "Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity." BioProcess international vol. 8,2 (2010): 26-35.
Gagnon P, Cheung CW, Lepin EJ, Wu AM, Sherman MA, Raubitschek AA, Yazaki PJ. Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity. Bioprocess Int. 2010 Feb;8(2):26-35. PMID: 21984873; PMCID: PMC3187938.
Copy Download .nbib Format: NLM
Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities.

Cancer & metabolism

Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christofk H, Prins RM, Lai A, Liau LM, Coppola G, Kornblum HI.
PMID: 29692895
Cancer Metab. 2018 Apr 17;6:4. doi: 10.1186/s40170-018-0177-4. eCollection 2018.

BACKGROUND: There is considerable interest in defining the metabolic abnormalities of IDH mutant tumors to exploit for therapy. While most studies have attempted to discern function by using cell lines transduced with exogenous IDH mutant enzyme, in this study,...

Cite
Garrett M, Sperry J, Braas D, et al. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab. 2018;6:4doi: 10.1186/s40170-018-0177-4.
Garrett, M., Sperry, J., Braas, D., Yan, W., Le, T. M., Mottahedeh, J., Ludwig, K., Eskin, A., Qin, Y., Levy, R., Breunig, J. J., Pajonk, F., Graeber, T. G., Radu, C. G., Christofk, H., Prins, R. M., Lai, A., Liau, L. M., Coppola, G., & Kornblum, H. I. (2018). Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer & metabolism, 64. https://doi.org/10.1186/s40170-018-0177-4
Garrett, Matthew, et al. "Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities." Cancer & metabolism vol. 6 (2018): 4. doi: https://doi.org/10.1186/s40170-018-0177-4
Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christofk H, Prins RM, Lai A, Liau LM, Coppola G, Kornblum HI. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab. 2018 Apr 17;6:4. doi: 10.1186/s40170-018-0177-4. eCollection 2018. PMID: 29692895; PMCID: PMC5905129.
Copy Download .nbib Format: NLM
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.

Frontiers in immunology

Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML.
PMID: 29379493
Front Immunol. 2018 Jan 04;8:1751. doi: 10.3389/fimmu.2017.01751. eCollection 2017.

The remarkable progress in engineering and clinical development of therapeutic antibodies in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by the United States Food and Drug Administration (FDA) of...

Cite
Almagro JC, Daniels-Wells TR, Perez-Tapia SM, et al. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Front Immunol. 2018;8:1751doi: 10.3389/fimmu.2017.01751.
Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M., & Penichet, M. L. (2017). Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Frontiers in immunology, 81751. https://doi.org/10.3389/fimmu.2017.01751
Almagro, Juan C, et al. "Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy." Frontiers in immunology vol. 8 (2017): 1751. doi: https://doi.org/10.3389/fimmu.2017.01751
Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Front Immunol. 2018 Jan 04;8:1751. doi: 10.3389/fimmu.2017.01751. eCollection 2017. PMID: 29379493; PMCID: PMC5770808.
Copy Download .nbib Format: NLM
Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.

Oncotarget

Kawaguchi K, Igarashi K, Li S, Han Q, Tan Y, Miyake K, Kiyuna T, Miyake M, Murakami T, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Unno M, Eilber FC, Hoffman RM.
PMID: 29416666
Oncotarget. 2017 Dec 12;9(1):915-923. doi: 10.18632/oncotarget.23185. eCollection 2018 Jan 02.

Melanoma is a recalcitrant disease. Melanoma patients with the BRAF-V600E mutation have been treated with the drug vemurafenib (VEM) which targets this mutation. However, we previously showed that VEM is not very effective against a BRAF-V600E melanoma mutant in...

Cite
Kawaguchi K, Igarashi K, Li S, et al. Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. Oncotarget. 2017;9(1):915-923doi: 10.18632/oncotarget.23185.
Kawaguchi, K., Igarashi, K., Li, S., Han, Q., Tan, Y., Miyake, K., Kiyuna, T., Miyake, M., Murakami, T., Chmielowski, B., Nelson, S. D., Russell, T. A., Dry, S. M., Li, Y., Unno, M., Eilber, F. C., & Hoffman, R. M. (2018). Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. Oncotarget, 9(1), 915-923. https://doi.org/10.18632/oncotarget.23185
Kawaguchi, Kei, et al. "Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models." Oncotarget vol. 9,1 (2018): 915-923. doi: https://doi.org/10.18632/oncotarget.23185
Kawaguchi K, Igarashi K, Li S, Han Q, Tan Y, Miyake K, Kiyuna T, Miyake M, Murakami T, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Unno M, Eilber FC, Hoffman RM. Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. Oncotarget. 2017 Dec 12;9(1):915-923. doi: 10.18632/oncotarget.23185. eCollection 2018 Jan 02. PMID: 29416666; PMCID: PMC5787523.
Copy Download .nbib Format: NLM
PD-1 blockade enhances the vaccination-induced immune response in glioma.

JCI insight

Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM.
PMID: 27453950
JCI Insight. 2016 Jul 07;1(10). doi: 10.1172/jci.insight.87059.

DC vaccination with autologous tumor lysate has demonstrated promising results for the treatment of glioblastoma (GBM) in preclinical and clinical studies. While the vaccine appears capable of inducing T cell infiltration into tumors, the effectiveness of active vaccination in...

Cite
Antonios JP, Soto H, Everson RG, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016;1(10)doi: 10.1172/jci.insight.87059.
Antonios, J. P., Soto, H., Everson, R. G., Orpilla, J., Moughon, D., Shin, N., Sedighim, S., Yong, W. H., Li, G., Cloughesy, T. F., Liau, L. M., & Prins, R. M. (2016). PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI insight, 1(10), . https://doi.org/10.1172/jci.insight.87059
Antonios, Joseph P, et al. "PD-1 blockade enhances the vaccination-induced immune response in glioma." JCI insight vol. 1,10 (2016). doi: https://doi.org/10.1172/jci.insight.87059
Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016 Jul 07;1(10). doi: 10.1172/jci.insight.87059. PMID: 27453950; PMCID: PMC4951098.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 155 entries